Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma
Moritz Peiseler, Frank Tacke
Cancers (2021) Vol. 13, Iss. 4, pp. 730-730
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 287
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel, Hanyang Liu, Adrien Guillot, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2668-2668
Open Access | Times Cited: 73
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression
Adrien Guillot, Marc Winkler, Milessa Silva Afonso, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 150-166
Closed Access | Times Cited: 54
Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
Melchor Alpízar Salazar, Samantha Estefanía Olguín Reyes, Andrea Medina Estévez, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 88-88
Open Access | Times Cited: 2
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 799-815
Closed Access | Times Cited: 53
Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
Ziwei Guo, Qinjuan Wu, Pengfei Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases
Xiaolin Xiao, Qichao Hu, Xinyu Deng, et al.
Pharmacological Research (2021) Vol. 175, pp. 106005-106005
Closed Access | Times Cited: 49
Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model
Hanyang Liu, Yin Guo, Marlene Kohlhepp, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 7
TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis
Xiaobo Wang, Sharon M. Zeldin, Hongxue Shi, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 910-920
Open Access | Times Cited: 33
Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses
Abinash Mahapatro, Fnu Bawna, Vikash Kumar, et al.
Clinical Nutrition ESPEN (2023) Vol. 57, pp. 475-486
Closed Access | Times Cited: 15
A review of liver fibrosis and cirrhosis regression
Michael J. Lee
Journal of Pathology and Translational Medicine (2023) Vol. 57, Iss. 4, pp. 189-195
Open Access | Times Cited: 14
Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study
Qingdan Liu, MeiLan K. Han, Meilan Li, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 14
A single approach, multiple insights: Harnessing spatial transcriptomics and proteomics to identify novel therapeutic targets of alcohol‐associated hepatitis
Eric Ham, Claudia R. Keating, Wei Qiu
Alcohol Clinical and Experimental Research (2025)
Closed Access
Novel Thiazolones for the Simultaneous Modulation of PPARγ, COX-2 and 15-LOX to Address Metabolic Disease-associated Portal Inflammation
Mai S. El-Shoukrofy, Azza Ismail, Reem H. Elhamammy, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117415-117415
Open Access
An integrative pharmacology-based study on the pharmacological activity and mechanism of xiaoji-chenpi formula (XCF) against MAFLD
Shufei Liang, Yang Dong, Ze Chang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Biodegradable Hypocrellin B nanoparticles coated with neutrophil membranes for hepatocellular carcinoma photodynamics therapy effectively via JUNB/ROS signaling
Zhiqiang Zhang, Dan Li, Yiming Cao, et al.
International Immunopharmacology (2021) Vol. 99, pp. 107624-107624
Closed Access | Times Cited: 29
Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review
Shahbaz Khan, Romil Saxena
Advances in Anatomic Pathology (2021) Vol. 28, Iss. 6, pp. 408-414
Open Access | Times Cited: 27
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
Pietro Torre, Benedetta Maria Motta, Roberta Sciorio, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 27
PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
Rosa Lombardi, Roberto Piciotti, Paola Dongiovanni, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2707-2707
Open Access | Times Cited: 21
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Elizabeth R. M. Zunica, Elizabeth C. Heintz, Christopher L. Axelrod, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4051-4051
Open Access | Times Cited: 20
Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease
Koen C. van Son, Lars Verschuren, Roeland Hanemaaijer, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1308-1308
Open Access | Times Cited: 11
Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma
Grigorios Papadopoulos, Eirini Giannousi, Aikaterini P. Avdi, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 3
Identification of biomarkers in nonalcoholic fatty liver disease: A machine learning method and experimental study
Na Han, Juan He, Lixin Shi, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 13
Lactiplantibacillus plantarum DSM20174 Attenuates the Progression of Non-Alcoholic Fatty Liver Disease by Modulating Gut Microbiota, Improving Metabolic Risk Factors, and Attenuating Adipose Inflammation
José Ignacio Riezu‐Boj, Miguel Barajas, Tania Pérez, et al.
Nutrients (2022) Vol. 14, Iss. 24, pp. 5212-5212
Open Access | Times Cited: 12
Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma
Massimiliano Cadamuro, Samantha Sarcognato, Riccardo Camerotto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4748-4748
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top